CoChat

A Versatile and Scalable Two-Step Ion-Exchange Chromatography Process for the Purification of Recombinant Adeno-associated Virus Serotypes-2 and -5

Open access
Brument, Nicole, Morenweiser, Robert, Blouin, Véronique, Toublanc, Estelle, Raimbaud, Isabelle, Chérel, Yan, Folliot, Sébastien, Gaden, Florence, Boulanger, Pierre, Kroner-Lux, Gabrielle, Moullier, Philippe, Rolling, Fabienne, Salvetti, Anna · 2002 · Molecular Therapy
Cited by 87

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Here we describe the development of a two-step chromatography process based on the use of ion-exchange resins for the purification of recombinant adeno-associated virus (rAAV) serotypes-2 and-5. In vitro and in vivo results demonstrate that this method, which does not require any prepurification step of the cell lysate, can be applied to obtain highly pure rAAV2 and rAAV5 stocks. As such,this procedure can be easily transferred in vector cores and also scaled up, allowing the direct comparison of these two, and potentially other, AAV serotypes in large animal models.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1006/mthe.2002.0719

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 29

  1. Snyder, 1999, Adeno-associated virus-mediated gene delivery, J. Gene Med, 1, 166, 10.1002/(SICI)1521-2254(199905/06)1:3<166::AID-JGM34>3.0.CO;2-Z · DOI · Paper page
  2. Rabinowitz, 2002, Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity, J. Virol, 76, 791, 10.1128/JVI.76.2.791-801.2002 · DOI · Paper page
  3. Zabner, 2000, Adeno-associated virus type 5 (AAV5) but not AAV2 binds to the apical surfaces of airway epithelia and facilitates gene transfer, J. Virol, 74, 3852, 10.1128/JVI.74.8.3852-3858.2000 · DOI · Paper page
  4. Grimm, 1998, Novel tools for production and purification of recombinant adeno-associated virus vectors, Hum. Gene Ther, 9, 2745, 10.1089/hum.1998.9.18-2745 · DOI · Paper page
  5. Clark, 1995, Cell lines for the production of recombinant adeno-associated virus, Hum. Gene Ther, 6, 1329, 10.1089/hum.1995.6.10-1329 · DOI · Paper page
  6. Inoue, 1998, Packaging cells based on inducible gene amplification for the production of adeno-associated virus vectors, J. Virol, 72, 7024, 10.1128/JVI.72.9.7024-7031.1998 · DOI · Paper page
  7. Liu, X., Voulgaropoulou, F., Chen, R., Johnson, P. R., and Clark, K. R.2000. Selective rep-cap gene amplification as a mechanism for high-titer recombinant AAV production from stable cell lines. Mol. Ther.2: 394–403, · DOI · Paper page
  8. Chadeuf, 2000, Efficient recombinant adeno-associated virus production by a stable rep-cap HeLa cell line correlates with adenovirus-induced amplification of the integrated rep-cap genome, J. Gene Med, 2, 260, 10.1002/1521-2254(200007/08)2:4<260::AID-JGM111>3.0.CO;2-8 · DOI · Paper page
  9. Gao, 2000, Purification of recombinant adeno-associated virus vectors by column chromatography and its performance in vivo, Hum. Gene Ther, 11, 2079, 10.1089/104303400750001390 · DOI · Paper page
  10. Mathews, 2002, Recombinant adeno-associated viral vector production using stable packaging and producer cell lines, Methods Enzymol, 346, 393, 10.1016/S0076-6879(02)46068-5 · DOI
  11. Zolotukhin, 1999, Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield, Gene Ther, 6, 973, 10.1038/sj.gt.3300938 · DOI · Paper page
  12. Tamayose, 1996, A new strategy for large-scale preparation of high-titer recombinant adeno-associated virus vectors by using packaging cell lines and sulfonated cellulose column chromatography, Hum. Gene Ther, 7, 507, 10.1089/hum.1996.7.4-507 · DOI · Paper page
  13. Debelak, 2000, Cation-exchange high-performance liquid chromatography of recombinant adeno-associated virus type 2, J. Chromatogr, B 740, 195, 10.1016/S0378-4347(00)00100-6 · DOI
  14. Auricchio, A., O'Connor, E., Hildinger, M., and Wilson, J. M.2001. A single-step affinity column for purification of serotype-5 based adeno-associated viral vectors. Mol. Ther.4: 372–374, · DOI · Paper page
  15. Drittanti, 2001, Optimised helper virus-free production of high-quality adeno-associated virus vectors, J. Gene Med, 3, 59, 10.1002/1521-2254(2000)9999:9999<::AID-JGM152>3.0.CO;2-U · DOI · Paper page
  16. O'Riordan, 2000, Scaleable chromatographic purification process for recombinant adeno-associated virus (rAAV), J. Gene Med, 2, 444, 10.1002/1521-2254(200011/12)2:6<444::AID-JGM132>3.0.CO;2-1 · DOI
  17. Anderson, 2000, A method for the preparation of highly purified adeno-associated virus using affinity column chromatography, protease digestion and solvent extraction, J. Virol. Methods, 85, 23, 10.1016/S0166-0934(99)00150-0 · DOI
  18. Clark, 1999, Highly purified recombinant adeno-associated virus vectors are biologically active and free of detectable helper and wild-type viruses, Hum. Gene Ther, 10, 1031, 10.1089/10430349950018427 · DOI · Paper page
  19. Potter, 2002, Streamlined large-scale production of recombinant adeno-associated virus (rAAV) vectors, Methods Enzymol, 346, 413, 10.1016/S0076-6879(02)46069-7 · DOI
  20. Auricchio, 2001, Isolation of highly infectious and pure adeno-associated virus type 2 vectors with a single-step gravity-flow column, Hum. Gene Ther, 12, 71, 10.1089/104303401450988 · DOI · Paper page
  21. Chiorini, 1999, Cloning and characterization of adeno-associated virus type 5, J. Virol, 73, 1309, 10.1128/JVI.73.2.1309-1319.1999 · DOI · Paper page
  22. Kaludov, 2001, Adeno-associated virus serotype 4 (AAV4) and AAV5 both require sialic acid binding for hemagglutination and efficient transduction but differ in sialic acid linkage specificity, J. Virol, 75, 6884, 10.1128/JVI.75.15.6884-6893.2001 · DOI · Paper page
  23. Zhang, 1994, Adenovirus inhibition of cell translation facilitates release of virus particles and enhances degradation of the cytokeratin network, J. Virol, 68, 2544, 10.1128/JVI.68.4.2544-2555.1994 · DOI
  24. Vellekamp, 2001, Empty capsids in column-purified recombinant adenovirus preparations, Hum. Gene Ther, 12, 1923, 10.1089/104303401753153974 · doi:10.1089/104303401753153974
  25. Bantel-Schaal, 2002, Endocytosis of adeno-associated virus type 5 leads to accumulation of virus particles in the Golgi compartment, J. Virol, 76, 2340, 10.1128/jvi.76.5.2340-2349.2002 · DOI · Paper page
  26. Salvetti, 1998, Factors influencing recombinant adeno-associated virus production, Hum. Gene Ther, 9, 695, 10.1089/hum.1998.9.5-695 · DOI · Paper page
  27. Graham, F. L., and Prevec, L.1991. Manipulation of adenovirus vectors. In Gene Transfer and ProtocolE. J. Murray, Ed., Vol. 7, pp. 109–128. Humana Press, Clifton, NJ. · DOI · Paper page
  28. Samulski, R. J., Chang, L. S., and Shenk, T.1989. Helper-free stocks of recombinant adeno-associated viruses: Normal integration does not require viral gene expression. J. Virol. 63: 3822–3828. · DOI · Paper page
  29. Favre, 2000, Hyaluronidase enhances recombinant adeno-associated virus (rAAV)-mediated gene transfer in the rat skeletal muscle, Gene Ther, 7, 1417, 10.1038/sj.gt.3301256 · DOI

Cited by

See all 87

Metadata

Authors
Brument, N., Morenweiser, R., Blouin, V., Toublanc, E., Raimbaud, I., Chérel, Y., Folliot, S., Gaden, F., Boulanger, P., Kroner-Lux, G., Moullier, P., Rolling, F., & Salvetti, A.
Venue
Molecular Therapy
Publisher
Elsevier BV
Published
2002-11
Volume
6
Issue
5
Pages
678-686
ISSN
1525-0016 (ISSN-L)
OpenAlex
W4245087155
Cited by
87
References
6
FWCI
3.34
Type
journal article
Language
en
Open access
hybrid
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.